NCT02600559

Brief Summary

This is an 8-week, multicenter, open-label study in which eligible subjects with a history of otitis media requiring TT placement will receive 6 mg OTO-201 to each ear. The study is designed to evaluate the safety and efficacy of OTO-201 in subjects undergoing TT placement with common concurrent surgeries and any middle ear effusion status.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
501

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Oct 2015

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

November 5, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 9, 2015

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
4.2 years until next milestone

Results Posted

Study results publicly available

September 22, 2020

Completed
Last Updated

October 19, 2020

Status Verified

September 1, 2020

Enrollment Period

9 months

First QC Date

November 5, 2015

Results QC Date

September 1, 2020

Last Update Submit

September 21, 2020

Conditions

Keywords

Otitis mediaEar infectionTympanostomy tubes

Outcome Measures

Primary Outcomes (2)

  • Number of Subjects With Post-surgical Otorrhea

    Absence or presence of otorrhea (drainage from the middle ear)

    Week 4

  • Number of Subjects With Post-surgical Otorrhea

    Absence or presence of otorrhea (drainage from the middle ear)

    8 weeks

Secondary Outcomes (4)

  • Adverse Events

    Up to Eight Weeks

  • Caregiver Burden - Ear Discharge Control

    Week 4

  • Caregiver Burden - Ear Discharge Control

    Week 8

  • Caregiver Burden - Ear Drops Administration

    Week 8

Study Arms (1)

0.1 mL OTO-201

EXPERIMENTAL

Ciprofloxacin

Drug: OTO-201 (ciprofloxacin)

Interventions

Also known as: OTIPRIO
0.1 mL OTO-201

Eligibility Criteria

Age6 Months - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Subject is a male or female aged 6 months to 17 years, inclusive
  • Subject has a history of otitis media requiring bilateral tympanostomy tube placement
  • Subject's caregiver is willing to comply with the protocol and attend all study visits

You may not qualify if:

  • Subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with TT placement
  • Subject has been designated for any other surgical procedure that would occur concurrently with TT placement, except adenoidectomy, airway endoscopy, nasal endoscopy, and nasal cautery for epistaxis
  • Subject has a history of sensorineural hearing loss

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Email Otonomy Central Contact for Trial Locations

San Diego, California, 92121, United States

Location

MeSH Terms

Conditions

Otitis MediaOtitis

Interventions

Ciprofloxacin

Condition Hierarchy (Ancestors)

Ear DiseasesOtorhinolaryngologic Diseases

Intervention Hierarchy (Ancestors)

Fluoroquinolones4-QuinolonesQuinolonesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title
Medical Information Call Center
Organization
Otonomy, Inc.

Study Officials

  • Dean Hakanson, MD

    Otonomy, Inc.

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 5, 2015

First Posted

November 9, 2015

Study Start

October 1, 2015

Primary Completion

July 1, 2016

Study Completion

July 1, 2016

Last Updated

October 19, 2020

Results First Posted

September 22, 2020

Record last verified: 2020-09

Locations